-- Biocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin TendersBengaluru, Karnataka, India and Johor, Malaysia – July 2, 2026Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation-led global biopharmaceutical company, announced that its long-standing partner, Duopharma Biotech Berhad (“Duopharma Biotech”) via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over MYR 225 million this year. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to high-quality, cost-effective insulin therapies for people living with diabetes in Malaysia. Bhd., said: “Biocon’s partnership with Duopharma Biotech has helped expand access to insulin therapies for patients in Malaysia. Biocon has been working with Duopharma Biotech since 2016 to address Malaysia’s growing diabetes burden. Bhd., a stepdown subsidiary of Biocon Limited, operates one of Asia’s largest integrated insulin facilities for recombinant human insulin and insulin analog products.